Zofková I, Táborský P, Bednár J, Nedvídková J
Institute of Endocrinology, Prague/CSFR.
Exp Clin Endocrinol. 1992;99(1):54-6. doi: 10.1055/s-0029-1211133.
The stimulating effect of calcitriol, administered in the dose of 3 micrograms/day for four days, on the thyrotropic and lactotropic secretion has been proved in earlier studies in healthy humans. The present study was undertaken to confirm or eliminate the stimulatory action of the drug using increasing dosages of 0.75-1.50 micrograms/day for one month. In spite of the fact, that the biologically efficient levels of calcitriol were attained (confirmed indirectly by the rise of urinary calcium excretion, p less than 0.01), the stimulating effect of calcitriol on the basal and TRH induced thyrotropic and lactotropic secretion has not been manifested. In conclusion, the clinical importance of stimulating effect of calcitriol on the thyrotropic and lactotropic secretion is neglected, if only commonly accepted therapeutic dosages up to 1.50 micrograms/day are used.
在早期针对健康人的研究中,已证实每日服用3微克剂量的骨化三醇,持续四天,对促甲状腺素和促乳素分泌具有刺激作用。本研究旨在通过使用每日0.75 - 1.50微克递增剂量,持续一个月,来确认或消除该药物的刺激作用。尽管已达到骨化三醇的生物有效水平(通过尿钙排泄增加间接证实,p < 0.01),但骨化三醇对基础及促甲状腺激素释放激素(TRH)诱导的促甲状腺素和促乳素分泌的刺激作用并未显现。总之,如果仅使用高达每日1.50微克的常用治疗剂量,骨化三醇对促甲状腺素和促乳素分泌的刺激作用的临床重要性可被忽略。